$15.37−0.99 (−6.05%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Scribe Therapeutics (SCTX) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsHow we compute thisNot investment advice
The 13F summary for SCTX is still being assembled from the full list of filers and was not ready when this page was built. It appears on a reload in a few minutes. No partial count is shown in its place, so that part of a quarter is never read as all of it.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Jul 28, 2026 | Aghazadeh Behzad | director | Acquired · Open-market buy | 7,905 | $18.25 | ↗ |
| Jul 27, 2026 | AH Bio Fund II, L.P. | 10% owner | Acquired · Derivative conversion | 2,051,742 | — | ↗ |
| Jul 27, 2026 | AH Bio Fund II, L.P. | 10% owner | Acquired · Derivative conversion | 697,650 | — | ↗ |
| Jul 27, 2026 | AH Bio Fund II, L.P. | 10% owner | Acquired · Open-market buy | 333,333 | $15.00 | ↗ |
| Jul 27, 2026 | AH Bio Fund II, L.P. | 10% owner | Disposed · Derivative conversion | 12,150,003Series A Preferred Stock | — | ↗ |
| Jul 27, 2026 | AH Bio Fund II, L.P. | 10% owner | Disposed · Derivative conversion | 4,131,344Series B Preferred Stock | — | ↗ |
| Jul 27, 2026 | GORDON CARL L | director | Acquired · Derivative conversion | 348,825 | — | ↗ |
| Jul 27, 2026 | GORDON CARL L | director | Acquired · Open-market buy | 1,000,000 | $15.00 | ↗ |
| Jul 27, 2026 | GORDON CARL L | director | Disposed · Derivative conversion | 2,065,672Series B Preferred Stock | — | ↗ |
| Jul 27, 2026 | ORBIMED ADVISORS LLC | director | Acquired · Derivative conversion | 348,825 | — | ↗ |
| Jul 27, 2026 | ORBIMED ADVISORS LLC | director | Acquired · Open-market buy | 1,000,000 | $15.00 | ↗ |
| Jul 27, 2026 | ORBIMED ADVISORS LLC | director | Disposed · Derivative conversion | 2,065,672Series B Preferred Stock | — | ↗ |
| Jul 27, 2026 | Doudna Jennifer A | 10% owner | Acquired · Derivative conversion | 12,511 | — | ↗ |
| Jul 27, 2026 | Doudna Jennifer A | 10% owner | Disposed · Derivative conversion | 74,088Series A-1 Preferred Stock | — | ↗ |
| Jul 24, 2026 | Aghazadeh Behzad | director | Acquired · Open-market buy | 2,333,333 | $15.00 | ↗ |
| Jul 24, 2026 | Aghazadeh Behzad | director | Acquired · Open-market buy | 50,000 | $22.31 | ↗ |
| Jul 23, 2026 | Staahl Brett | 10% owner | Acquired · Grant / award | 19,385Stock Option (Right to Buy) | — | ↗ |
| Jul 23, 2026 | Staahl Brett | 10% owner | Acquired · Grant / award | 19,385Performance-based Stock Option (Right to Buy) | — | ↗ |
| Jul 23, 2026 | Lucas Svetlana | Chief Business Officer | Acquired · Open-market buy | 3,000 | $15.00 | ↗ |
| Jul 23, 2026 | Lucas Svetlana | Chief Business Officer | Acquired · Grant / award | 109,426Stock Option (Right to Buy) | — | ↗ |
13F holdings are reported quarterly; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Not investment advice.

